Swift Biosciences, a leading provider of innovative library prep solutions for genomic sequencing, today named industry veteran Nathan Wood as its new CEO. The hire is the latest in a recent series of strategic moves by Swift to solidify its position serving the personalized medicine, drug discovery and disease research markets.
Swift Biosciences today announced the commercial release of its Accel-Amplicon Plus™ Cancer NGS Panels, a suite of nine tumor-specific and focused gene panels to facilitate targeted cancer sequencing. The Accel-Amplicon technology enables simultaneous detection of single nucleotide variants, copy number variants and small insertion and deletions to achieve comprehensive and exon-level hotspot coverage of clinically-relevant genes.
Swift Biosciences, a leading provider of innovative library prep solutions for next-generation sequencing (NGS), today announced the launch of a new single-cell methylation sequencing method based on its Accel-NGS® Adaptase™ technology, an efficient and robust NGS-prep solution for whole-genome bisulfite sequencing at single-cell resolution.
Swift Biosciences, a leading provider of innovative library prep solutions for genomic sequencing, today announced the completion of a Series D funding raise of $12.2 million. The company also announced the addition of two new directors to its board, positioning the company for accelerated growth.